We are thrilled to share with you an incredible milestone in our journey to revolutionize canine cancer treatment. Thanks to your unwavering support and dedication, we have now enrolled over 5,000 dogs in the FidoCure platform! This achievement is a testament to the trust you have placed in our innovative approach and the positive impact we are making together in the lives of dogs and their families.
Since 2016, FidoCure has been at the forefront of cutting-edge research in canine cancer treatment. The 5,000 brave dogs enrolled in our platform have not only received personalized care but have also been instrumental in our ongoing research efforts. We are proud to share our collaborative work that's resulted in the publication of scientific papers in Nature, NPJ Precision Oncology, Elsevier and Veterinary and Comparative Oncology, showcasing the groundbreaking insights we have gained through this remarkable journey together.
In 2024 alone, we have had the privilege of presenting our research findings in the company of some of the most respected researchers in the field at conferences such as the World Veterinary Cancer Congress (WVCC) and the American Association for Cancer Research (AACR) Annual Meeting.
FidoCure extends our heartfelt gratitude to the veterinary community, our research partners, pet parents and the entire team at FidoCure for their trust and dedication. Together, we are making a positive impact on the lives of dogs and their families.
As we move forward, FidoCure remains committed to fighting cancer on both ends of the leash. We remain committed to expanding our reach, refining our platform, and advancing canine cancer research to benefit even more dogs and humans in the future.
